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ABSTRACT 15 
 16 
MTHFR is an important enzyme in the metabolism of folic acid and is crucial for reproductive 17 
function. Variation in the sequence of MTHFR has been implicated in subfertility, but definitive 18 
data is lacking. In the present study a detailed analysis of two common MTHFR polymorphisms 19 
(c.677C>T and c.1298A>C) was performed. Additionally, for the first time, the frequencies of 20 
different MTHFR alleles were assessed in preimplantation embryos. Several striking discoveries 21 
were made. Firstly, results demonstrated that maternal MTHFR c.1298A>C genotype strongly 22 
influences the likelihood of a pregnancy occurring, with the 1298C allele being significantly 23 
overrepresented amongst women who have undergone several unsuccessful assisted 24 
 2 
reproductive treatments. Secondly, parental MTHFR genotypes were shown to effect the 25 
production of aneuploid embryos, indicating that MTHFR is one of the few known human 26 
genes with the capacity to modulate rates of chromosome abnormality. Thirdly, an unusual 27 
deviation from Hardy-Weinberg equilibrium was noted for the c.677C>T polymorphism in 28 
subfertile patients, especially those who had experienced recurrent failure of embryo 29 
implantation or miscarriage, potentially explained by a rare case of heterozygote 30 
disadvantage. Finally, a dramatic impact of the MTHFR 677T allele on the capacity of 31 
chromosomally normal embryos to implant is described. Not only do these findings raise a 32 
series of interesting biological questions, but they also argue that testing of MTHFR could be of 33 
great clinical value, identifying patients at high-risk of implantation failure and revealing the 34 
most viable embryos during in vitro fertilization (IVF) cycles.  35 
 36 
INTRODUCTION 37 
Folic acid is an important B vitamin essential for human reproduction 1. The processing of folic 38 
acid and other dietary folates is vital for many key processes such as amino acid metabolism, 39 
purine and pyrimidine synthesis, and methylation of nucleic acids, proteins and lipids 2. These 40 
folate dependent functions are required for DNA synthesis and repair, control of gene 41 
expression and many other biological processes of fundamental importance for cell division 42 
and embryo development 3, 4.  43 
Folate deficiency (genetically determined or due to dietary restriction) results in a higher 44 
frequency of uracil misincorporation into DNA, disruption of nucleic acid integrity, slower DNA 45 
replication and an increased risk of chromosome breakage. Affected cells experience elevated 46 
rates of apoptosis and necrosis 5-7. Insufficient folate or folic acid intake has also been shown 47 
to negatively affect specific reproductive functions; it has a detrimental effect on many 48 
processes involved in oocyte development, acquisition of endometrial receptivity, embryo 49 
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implantation and also in the maintenance of pregnancy 8-11. Several animal model studies have 50 
shown that maternal folate deficiency prior to conception and during gestation has a negative 51 
effect on female fertility and fetal viability, emphasizing the important role of folate during 52 
mammalian folliculogenesis and fetal development 12-14. 53 
Numerous variations in genes involved in folate metabolism have been identified. In some 54 
cases, these mutations and polymorphisms alter the efficiency of pathways involved in folate 55 
generation and processing. In terms of prevalence and impact, genetic variations affecting the 56 
5,10-methylenetetrahydrofolate reductase gene (MTHFR) are among the most biologically 57 
important. MTHFR is a key enzyme that plays an important role in catalysing the conversion of 58 
5,10-methylenetetrahydrofolate into 5-methylenetetrahydrofolate, the predominant 59 
circulating form of folate. This molecule provides the single carbon needed for the synthesis of 60 
nucleotides, the remethylation of homocysteine to methionine, the synthesis of S-61 
adenosylmethionine and the methylation of DNA, proteins, neurotransmitters and 62 
phospholipids 15, 16.  63 
More than 20 DNA sequence variants and polymorphisms within the MTHFR gene have been 64 
described 17. Two of the most investigated are single nucleotide polymorphisms (SNPs) at the 65 
mRNA positions 677 (rs1801133) and 1298 (rs1801131) 15, 18. The well-characterised MTHFR 66 
c.677C>T transition, which results in an alanine to valine substitution (p.Ala222Val) in the 67 
predicted catalytic domain of MTHFR, renders the enzyme thermolabile and leads to a 68 
reduction in MTHFR activity. Homozygous and heterozygous individuals have in vitro MTHFR 69 
activity reduced by about 70% and 35%, respectively 15. Homozygosity for the 677T allele is 70 
associated with elevated circulating homocysteine in some individuals, predominantly those 71 
who have a low plasma folate level 19. In these individuals, the level of plasma homocysteine 72 
can be lowered by folic acid supplementation 20.  73 
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The other common polymorphism in the MTHFR gene, c.1298A>C transversion, results in a 74 
glutamate to alanine substitution (p.Glu429Ala) within a presumed regulatory domain of 75 
MTHFR 18, 21. The 1298C allele leads to decreased enzyme activity, although to a lesser extent 76 
than the 677T allele. Individuals who are homozygous for the 1298C allele have about a 40% 77 
reduction in enzyme activity in vitro, but do not appear to have higher plasma homocysteine 78 
levels than controls 18, 21, 22. However, individuals who are compound heterozygous for the 79 
677T and the 1298C alleles (MTHFR c.677C/T plus c.1298A/C genotype) have a 40-50% 80 
reduction in enzyme activity in vitro and a biochemical profile similar to that seen among 677T 81 
homozygotes, with increased homocysteine and decreased folate levels. The c.1298A>C 82 
polymorphism by itself may have clinically important effects under conditions of low folate 83 
intake or during times of high folate requirements, such as pregnancy and embryogenesis 18. 84 
Despite the fact that many studies have explored the relationship between MTHFR 85 
polymorphisms and aspects of human reproduction, the biochemical influence and clinical 86 
relevance of these variations is still debated. Some authors have reported an association of 87 
certain genotypes with an increased risk of miscarriage, a potential consequence of poor 88 
vascularization of the placental area of individuals carrying minor alleles 23-26. Others have 89 
described a link between c.677C>T and c.1298A>C polymorphisms and the likelihood of 90 
aneuploid conceptions, pointing out the possible influence of MTHFR on chromosome non-91 
disjunction and other processes involved in chromosome segregation 26-29. More recent reports 92 
have explored the impact of these polymorphisms in patients undergoing IVF treatment, 93 
suggesting an influence of some MTHFR variants on embryo implantation 30, 31. However, this 94 
remains controversial, other studies failing to detect evidence of the proposed association 32-34. 95 
A comprehensive analysis of the genotypes of individuals affected by fertility problems and of 96 
the embryos they produce is required in order to obtain a better understanding of the effects 97 
of MTHFR gene variants on reproduction in general and on assisted reproduction in particular. 98 
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In this study we aimed to answer several questions. Firstly, does MTHFR have a significant 99 
influence on the fertility of groups of patients with specific reproductive histories (e.g. patients 100 
with a history of recurrent miscarriages or patients suffering repetitive implantation failure 101 
after IVF treatment)? Secondly, do maternal and paternal MTHFR genotypes influence the 102 
frequency at which aneuploid embryos are produced? Finally, does the MTHFR genotype have 103 
an impact on the developmental competence of an embryo? It was hoped that this detailed 104 
analysis, including genotyping of embryos as well as adults, would help to define the aspects of 105 
human reproduction affected by genetically inherited defects of the MTHFR gene. 106 
 107 
MATERIALS AND METHODS 108 
 109 
Cohort selection 110 
The initial study group consisted of 138 patients (92 females and 46 males) undergoing 111 
assisted reproductive treatment (ART) and having aneuploidy screening of their embryos for a 112 
variety of reasons including recurrent miscarriage, repetitive implantation failure and 113 
advanced maternal age. Additionally a well-matched control population was assessed, 114 
composed of 161 fertile individuals that had previously achieved at least one successful 115 
pregnancy. Both groups were of varied ethnic origin, primarily European, but also including 116 
individuals of North African and Southeast Asian descent. The ethnic mix of the two groups 117 
was considered to be equivalent. In addition to the DNA samples from adults, 193 blastocysts, 118 
previously screened for aneuploidy using microarray Comparative Genomic Hybridisation 119 
(aCGH) were also available for analysis.  120 
 121 
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Ethics  122 
Ethical approval and signed patient consent for research had been obtained for all patient 123 
samples used in this study. No embryos were biopsied specifically for the purpose of this 124 
study. The embryo DNA samples assessed consisted of surplus whole genome amplification 125 
products, leftover following routine aneuploidy screening. Ethical approval for this study was 126 
obtained from the North London REC 3 (10/H0709/26) and Western IRB (20060680 and 127 
20131473). 128 
 129 
MTHFR genotyping 130 
Genomic DNA was extracted from blood using the QIAamp DNA Blood Mini Kit (Qiagen, 131 
Hilden, Germany). Amplification of the c.677C>T region of the MTHFR gene was performed 132 
using the primer pairs 5’-TGAAGGAGAAGGTGTCTGCGGGA-3’ (forward primer) and 5’-133 
AGGACGGTGCGGTGAGAGTG-3’ (reverse primer) described by Frosst et al. 15. Amplification of 134 
the c.1298A>C region of the MTHFR gene was accomplished using the forward (5’-135 
CTTTGGGGAGCTGAAGGACTACTAC-3’) and reverse (5’-CACTTTGTGACCATTCCGGTTTG-3’) 136 
primers reported by van der Put et al. 18. PCR amplifications (25 µl volume) consisted of the 137 
following: 5 ng of genomic DNA in the case of patients and controls or 0.5 µl of Sureplex-138 
amplified DNA in the case of biopsied material from preimplantation embryos; 10 pmol each 139 
of the c.677C>T or c.1298A>C forward and reverse primers; 0.625 units of Perfect Taq DNA 140 
polymerase (5 prime GmbH, Hamburg, Germany); 0.2mM of dNTPs (Thermo Scientific, 141 
Colchester, UK) in 1x PCR Buffer (5 prime GmbH, Hamburg, Germany). Amplification of the 142 
correct fragment was initially confirmed by uni-directional DNA sequencing followed by 143 
comparison and alignment to the NCBI Reference Sequence NG_013351.1.  144 
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PCR was followed by minisequencing as described by Zetterberg et al. (2002) with some 145 
modifications. Prior to the minisequencing reaction, 0.5 µl of PCR product was purified using 146 
ExoSAP-IT (Affymetrix, High Wycombe, UK) following the manufacturer’s instructions. 147 
Minisequencing was then conducted in a final volume of 5 μl, consisting of 0.5 µl of each of the 148 
purified MTHFR c.677C>T and c.1298A>C PCR products, 2.5 µl SNaPshot Multiplex Ready 149 
Reaction Mix (Applied Biosystems, United Kingdom) and 1 pmol of each of the minisequencing 150 
primers: 5’-T(20)GCGTGATGATGAAATC-G-3’ (reverse primer) for MTHFR c.677C>T; 5’-151 
GGAGCTGACCAGTGAAG-3’ (forward primer) for c.1298A>C. The poly (T) sequence of the 152 
former was added to modify the electrophoretic mobility of the primer. The cycling protocol 153 
was 25 cycles of 96°C/10 seconds, 50°C/5 seconds and 60°C/30 seconds. Minisequencing 154 
products were analysed by capillary electrophoresis on an ABI 3130 Genetic Analyzer (Applied 155 
Biosystems, UK). The reaction included 9.25μl Hi-Di Formamide (Applied Biosystems, UK, 156 
0.25μl GeneScan-120LIZ Size 157 
product. Incubation at 95°C for 3 minutes in order to denature the minisequencing product 158 
was performed prior to electrophoresis. Data was subsequently visualized and analysed using 159 
the GeneMapper software (Applied Biosystems, UK). 160 
Embryo DNA samples consisted of trophectoderm biopsy specimens (~5 cells removed at the 161 
blastocyst stage), which had been subjected to whole genome amplification (SurePlex, 162 
Rubicon, USA). The biopsies were performed for the purpose of routine preimplantation 163 
genetic screening (PGS) using microarray-comparative genomic hybridisation (aCGH) 164 
(described below). In order to assess the polymorphisms, surplus SurePlex DNA was subjected 165 
to the same protocol as genomic DNA. 166 
 167 
 168 
 169 
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Confirmatory analysis on an independent population 170 
An entirely independent data set was available from 202 individuals (101 couples) evaluated 171 
using an alternative, microarray-based, methodology (CarrierMap, Recombine, USA). The 172 
CarrierMap test is primarily used for preconception carrier screening, evaluating couples 173 
considering starting a family for the presence of >1,700 mutations responsible for more than 174 
250 different genetic conditions. However, a number of polymorphisms of potential relevance 175 
to reproduction are also assessed, including the MTHFR c.677C>T and c.1298A>C 176 
polymorphisms. The data was divided into three separate groups: 28 of the couples tested 177 
were considered to be fertile, having achieved at least one pregnancy without the help of any 178 
assisted reproductive treatments (average of 1.9 pregnancies per couple) and having had no 179 
more than one previous miscarriage; 62 couples had a history of infertility and had undergone 180 
treatment using IVF or intrauterine insemination (IUI); 11 couples had received a formal 181 
diagnosis of recurrent miscarriage. 182 
 183 
Embryo aneuploidy testing 184 
Embryo chromosome analysis was accomplished by the use of a well validated aCGH method 185 
following the protocol described by Alfarawati et al. 35. Diagnosis of embryos was performed at 186 
the blastocyst stage and involved sampling and testing of 5 to 10 trophectoderm cells. Briefly, 187 
cells were lysed and their DNA amplified using whole genome amplification (SurePlex, 188 
Rubicon, USA). Amplified sample and reference DNAs from chromosomally normal individuals 189 
were labelled with Cy3 and Cy5 fluorochromes respectively and then hybridized to the probes 190 
of a bacterial artificial chromosome (BAC) microarray (24Sure, Illumina, Cambridge, UK). 191 
Chromosome losses and gains were revealed by differences in the fluorescence intensity 192 
corresponding to sample and reference DNAs for BAC probes derived from the affected 193 
chromosome or chromosomal region. Labelling of the amplified samples, hybridization to 194 
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microarray slides, post-hybridization washes and analyses were performed as described 195 
elsewhere 35. Published values for the accuracy rate for aCGH are >95% for biopsy specimens 196 
consisting of small numbers of trophectoderm cells 36, 37. 197 
 198 
Statistical analyses 199 
MTHFR c.677C>T and c.1298A>C allele and genotype frequencies were determined for each of 200 
the three populations initially investigated (subfertile patients, fertile controls and 201 
preimplantation embryos) and compared using a Chi-squared goodness of fit test. Genotype 202 
frequencies in all groups were also assessed for compliance with the Hardy-Weinberg 203 
equilibrium using GENEPOP v.4.2 software38, 39. Comparisons of patient genotypes with regards 204 
to sex, maternal age and reproductive history were also carried out using the same analysis. 205 
Similar analyses were carried out for the three populations with data obtained from 206 
Recombine (subfertile patients, fertile controls and patients with recurrent miscarriage). The 207 
proportion of aneuploid embryos (aneuploidy rate) produced by patients with specific MTHFR 208 
genotypes was assessed and compared using a T-test. In the case of preimplantation embryos, 209 
comparisons of the genotype frequencies of chromosomally normal and aneuploid embryos, 210 
normal embryos with successful or failed implantation, and embryos from patients with a 211 
variety of referral reasons were also determined and compared using Chi squared goodness of 212 
fit test. 213 
Statistical significance was defined as p<0.05 and all analyses were performed using the IBM 214 
SPSS Statistics Version 20 software (IBM Corporation, USA). 215 
 216 
RESULTS 217 
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MTHFR in subfertile patients  218 
A statistically significant increase in the frequency of the less common MTHFR 1298C allele was 219 
observed in subfertile patients compared to fertile controls (p=0.003), leading to a higher 220 
prevalence of individuals homozygous for 1298C and a lower incidence of patients 221 
homozygous for the major allele (1298A) (p=0.01 and p=0.02, respectively) (Table 1 and Figure 222 
1).  No differences were observed for allele or genotype frequencies for the MTHFR c.677C>T 223 
polymorphism. Analysis of the second population of samples tested using CarrierMap yielded 224 
similar results, with the frequency of 1298C homozygotes doubled in infertile couples.  225 
When data were subdivided by sex, the difference in the MTHFR c.1298A>C genotype 226 
frequency was clearly apparent in female patients. In comparison to controls, subfertile female 227 
patients displayed a significantly higher incidence of MTHFR c.1298CC homozygotes and a 228 
lower frequency of MTHFR c.1298AA homozygotes (p<0.01) (Table 2). In the male group a 229 
similar tendency was observed, but it was less pronounced and did not reach statistical 230 
significance. Within the fertile control group there were no differences in genotype 231 
frequencies between the two sexes. Examination of MTHFR c.677C>T polymorphism did not 232 
reveal any differences in the incidence of particular genotypes between males and females 233 
(Table 2). 234 
Genotype distributions of both the MTHFR c.677C>T and c.1298A>C polymorphisms in the 235 
fertile control group were in Hardy-Weinberg equilibrium. However, a deviation from expected 236 
genotype frequencies was found for MTHFR c.677C>T in subfertile patients due to a deficit of 237 
heterozygotes (p<0.01) (Figure S1). Analysis of patient subgroups revealed that this was 238 
particularly apparent in couples with a history of failed implantation or miscarriage. 239 
Investigation of the independent set of samples tested using CarrierMap yielded concordant 240 
data, with genotype frequencies in the infertile group and in patients with recurrent 241 
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miscarriage differing significantly from those expected for a population in equilibrium (p<0.001 242 
and p<0.01 respectively) (Figure S2).  243 
When both MTHFR polymorphisms were analysed in combination, no individuals carrying 244 
three or four mutant alleles (MTHFR c.677CT/c.1298CC, c.677TT/c.1298CA, c.677TT/c.1298CC) 245 
were detected in any of the populations studied, suggesting linkage disequilibrium between 246 
these two loci (Table S1). Based upon allele frequencies and protein function, it is likely that 247 
the ancestral MTHFR gene had a 677C/1298A haplotype. Mutation at the 677 nucleotide 248 
position later produced a 677T/1298A haplotype and, in an independent event, mutation at 249 
position 1298 produced a 677C/1298C haplotype. Consequently, 677T/1298C haplotypes can 250 
only be formed by recombination within the MTHFR gene, an extremely unlikely occurrence 251 
given the close proximity of the two polymorphisms. The existence of linkage disequilibrium 252 
was confirmed by G-test analysis (p<0.05). The specific combination of 677T and 1298C alleles 253 
did not appear to have any additive effect in terms of impact on fertility in this patient 254 
population. 255 
Patients were divided into groups according to their previous reproductive history, in an effort 256 
to determine whether differences in genotype frequencies were related to subfertility in 257 
general or to particular reproductive problems. Analysis revealed that the significant excess of 258 
MTHFR c.1298A>C homozygotes observed in the subfertile group was primarily attributable to 259 
patients that had experienced repetitive implantation failure (RIF, i.e. three of more in vitro 260 
fertilization treatments, including transfer of embryos to the uterus, but no pregnancy) relative 261 
to the control group (p<0.001) (Table 3). The difference in the incidence of 1298C 262 
homozygotes amongst patients with RIF was equally apparent for both males and females. No 263 
significant differences in genotype frequency were seen for any other category of patient 264 
(recurrent miscarriage [RM] or advanced maternal age [AMA]).  265 
 266 
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Parental MTHFR genotype and embryo aneuploidy 267 
The MTHFR genotypes of patients undergoing IVF were considered in relation to the 268 
proportion of chromosomally abnormal embryos they produced (aneuploidy rate). A 269 
significantly higher aneuploidy rate was found in those patients presenting with at least one 270 
MTHFR minor allele (MTHFR 677T or MTHFR 1298C) compared to those patients with none (T-271 
test, p=0.036) (Table 4). Patients homozygous for the major alleles showed a mean embryo 272 
aneuploidy rate (±SEM) of 58.8% (±6.3), considerably lower than the 70.2% (±2.2) average for 273 
patients carrying a minor allele for at least one of the two MTHFR polymorphisms studied. 274 
When patients were divided according to their sex, it became clear that maternal genotype 275 
was associated with embryo aneuploidy (p=0.028), whereas the paternal genotype did not 276 
have a significant effect.  277 
When the embryo aneuploidy rates and MTHFR genotypes for patients with different 278 
indications (AMA, RIF or RM) were compared, results showed that in the case of AMA and RM 279 
patients the presence of one minor allele in at least one of the two MTHFR polymorphisms 280 
analysed, was associated with a significantly higher level of affected embryos compared to 281 
those patients homozygous for the major alleles (p=0.045 and p=0.048, for AMA and RM 282 
respectively). Again, these effects were only observed in relation to maternal genotype. No 283 
differences were found in the group of RIF patients (p=0.72) (Table 4).  284 
The effect of embryonic MTHFR genotype  285 
MTHFR c.677C>T and c.1298A>C allele and genotype frequencies were calculated for the 193 286 
embryos tested. No significant differences were found when embryo allele and genotype 287 
frequencies were compared to those seen in adults (Table S2 and S3). When both MTHFR 288 
c.677C>T and c.1298A>C polymorphisms were analysed in combination, no embryos carrying 3 289 
or 4 mutant alleles (677CT/1298CC or 677TT/1298CA) were detected, mirroring the findings in 290 
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patients. No significant differences were observed when the genotype frequencies of euploid 291 
and aneuploid embryos were compared.  292 
Conversely, when comparing the genotype frequencies of chromosomally normal embryos 293 
that successfully implanted (n=19) with those euploid embryos that failed to implant (n=27), 294 
significant differences were observed for MTHFR c.677C>T (p<0.01). The incidence of embryos 295 
homozygous for the MTHFR 677 minor allele (677T) was elevated in non-viable embryos 296 
compared to those that successfully formed on-going pregnancies (Figure 2). One in four 297 
embryos experiencing failed implantation was homozygous for 677T whereas only one out of 298 
every 19 embryos that produced a pregnancy was homozygous for the same allele. The risk of 299 
implantation failure was two-fold higher for 677T homozygotes compared with 677C 300 
homozygotes (87.5% versus 45%) (Figure 3). Interestingly, significant differences in MTHFR 301 
c.677C>T genotype frequencies were also found between those embryos that failed to implant 302 
and the adult population composed of fertile and infertile subjects (p=0.04) (Figure S3). No 303 
such differences were detected between adults and embryos that successfully implanted 304 
(Table S3).  305 
A deviation from Hardy-Weinberg equilibrium, due to a deficit of heterozygote genotypes, was 306 
apparent for the total population of embryos (p<0.01), resembling that seen for the samples 307 
from subfertile adults. Further division of the embryos into different categories (e.g. based 308 
upon patient indication or ability to implant) resulted in groups too small for meaningful 309 
statistical analysis. Nonetheless, it may be relevant that the embryos that successfully 310 
implanted (n=19) had genotype frequencies in line with Hardy-Weinberg expectations, while 311 
those that failed to implant (n=27) displayed an apparent increase in the proportion of 312 
homozygotes at the expense of heterozygotes. This was, however, not statistically significant 313 
due the small sample size (Figure S4). No significant differences in genotype frequencies were 314 
found in the case of the MTHFR c.1298A>C polymorphism.  315 
 14 
DISCUSSION 316 
 317 
MTHFR genotype and implantation failure 318 
This study confirmed that the MTHFR c.1298A>C genotype has a strong influence on fertility. A 319 
higher prevalence of the 1298C allele, and a corresponding increase in the frequency of 320 
MTHFR c.1298C homozygotes, were observed for patients undergoing IVF treatment 321 
compared to fertile controls. This was later confirmed in an entirely independent population of 322 
patients, analysed using an alternative methodology. Analysis of different patient subgroups 323 
revealed that the increase in 1298C prevalence was most apparent in couples with a history of 324 
multiple unsuccessful IVF treatments. Amongst these patients the frequency of the 1298C 325 
allele was increased 4-fold from 0.06 (seen in fertile controls) to 0.24. Women within this 326 
category had received transfer of embryos to the uterus on at least three occasions, but 327 
without any pregnancy, indicating that the 1298C allele has a powerful impact on the ability of 328 
embryos to implant. The increase in 1298C frequency was principally observed in female 329 
patients, suggesting that reduced implantation rates may be related to an abnormal 330 
endometrial response or other maternal factors. Given the established reduction in MTHFR 331 
activity associated with homozygosity for the 1298C allele 18, 21, 22, it can be inferred that 332 
individuals with compromised MTHFR activity are at increased risk of experiencing recurrent 333 
implantation failure. It is noteworthy that an elevated 1298C allele frequency was also 334 
observed in subfertile males, albeit to a lesser extent than seen females, suggesting that male 335 
factors related to this polymorphism might also influence the likelihood of implantation. No 336 
increase in the prevalence of the 1298C allele was detected in embryos that failed to implant 337 
compared to those that produced a viable pregnancy, arguing against the possibility of an 338 
effect at the level of the embryo.  339 
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The implantation of the blastocyst into the endometrium is a complex process that involves 340 
multiple molecular interactions between trophoblastic and endometrial cells, including 341 
coagulation and fibrinolysis processes at the embryo-maternal interface 40, 41. It is conceivable 342 
that alteration of the functional activity of blood coagulation factors, related to diminished 343 
MTHFR activity, could affect the likelihood of implantation. There have been a number of 344 
publications reporting associations between inherited thrombophilic 345 
mutations/polymorphisms and recurrent unsuccessful IVF cycles 42, 43. It is undoubtedly true 346 
that appropriate coagulation processes, both maternal and placental, are of vital importance 347 
for pregnancy maintenance and are therefore of great relevance to miscarriage. This may be 348 
relevant to the distorted genotype frequencies of MTHFR polymorphisms observed in patients 349 
with recurrent pregnancy loss during this study. However, a role for coagulative processes at 350 
the time of implantation seems less likely. Perhaps more relevant in this regard are studies 351 
suggesting that folic acid concentration, modulated by MTHFR, has an important effect on 352 
trophoblast invasion, one of the very first steps of embryo implantation 44. Another possibility, 353 
potentially explaining increased rates of miscarriage and failure to implant, is that MTHFR 354 
variants influence levels of embryo aneuploidy (discussed below). Aneuploidy is extremely 355 
common in human preimplantation embryos and is believed to be the principal cause of 356 
implantation failure in both natural and assisted reproductive cycles 45-47. 357 
Unlike the c.1298A>C polymorphism, investigation of the other common MTHFR variant 358 
(c.677C>T) revealed no change in overall allele frequency for any of subfertile patient groups. 359 
However, a striking and unexpected discovery was that the two MTHFR c.677C>T alleles were 360 
not distributed in the expected proportions, resulting in a pronounced distortion of genotype 361 
frequencies (i.e. a deviation from Hardy-Weinberg equilibrium). Closer examination of the data 362 
revealed a deficit of MTHFR c.677C>T heterozygotes amongst patients with a history of 363 
recurrent implantation failure or miscarriage. Again, this data was subsequently confirmed by 364 
analysis of an independent set of samples using a different genotyping method. Interestingly, 365 
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within these patient groups, there was a four-fold overrepresentation of couples in which the 366 
male and female had opposite homozygous genotypes (e.g. male homozygous for 677C and 367 
female homozygous for 677T or vice versa). Clearly, such couples can only produce 368 
heterozygous embryos, leading us to hypothesize that the two MTHFR c.677C>T alleles might 369 
be incompatible at a molecular level, leading to the formation of defective MTHFR dimers 370 
(essentially resulting in a heterozygote disadvantage) 48, 49. An alternative possibility is that 371 
heterozygosity for c.677C>T is beneficial in terms of fertility and therefore less likely to be 372 
observed in patients undergoing fertility treatments. However, since 677T alleles are known to 373 
be associated with diminished MTHFR function, this seems doubtful. 374 
Investigation of preimplantation embryos produced by infertile couple demonstrated that 375 
deviation from expected c.677C>T genotype frequencies, mirroring those seen in the subfertile 376 
adults, can also be observed just a few days after conception. This suggests that the impact of 377 
the c.677C>T genotype must primarily be felt between fertilisation and the blastocyst stage. 378 
During this time, a period of five days, approximately half of all human embryos undergo 379 
developmental arrest and perish. It would be valuable to repeat the experiments described 380 
here on embryos that ceased developing during the first few days of life, in order to determine 381 
whether c.677C>T heterozygotes are at increased risk of developmental failure prior to 382 
blastocyst formation. 383 
 384 
Parental MTHFR genotype and embryo aneuploidy 385 
A significantly higher proportion of aneuploid embryos was found for patients carrying one or 386 
more alleles associated with reduced MTHFR activity compared to those with none. Patients 387 
with 677T and/or 1298C alleles showed a mean embryo aneuploidy rate 20% higher than that 388 
of patients homozygous for the major (fully functional) MTHFR alleles. The association of 389 
MTHFR genotype with embryo aneuploidy was more evident for female patients than males, 390 
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indicating that the elevated rate of chromosome abnormality is primarily related to meiotic 391 
errors occurring during oogenesis. Results are suggestive of an influence in males as well, but 392 
an increased sample size would be needed to confirm this statistically. The impact of MTHFR 393 
genotype on the production of aneuploid embryos was most pronounced for women of 394 
advanced reproductive age (>37 years) or those with a history of recurrent miscarriage. This 395 
may be an indication that these patients are particularly sensitive to problems associated with 396 
compromised MTHFR function and that an increased incidence of embryo chromosomal 397 
abnormalities may be contributing to their difficulties achieving a viable pregnancy. 398 
An influence of maternal MTHFR genotype on embryo viability was also suggested by Haggarty 399 
et al. 50. In their study, women homozygous for the 1298C allele were less likely to have a live 400 
birth after IVF compared to women homozygous for the more common 1298A allele. However, 401 
no chromosome analysis was carried out, so it is unclear whether the reduced viability was 402 
related to aneuploidy or other embryonic or maternal factors. Studies trying to establish an 403 
association between folic acid metabolism and preimplantation embryo development have 404 
shown that MTHFR is expressed in both human oocytes and embryos 51, 52. Folic acid is present 405 
in the follicular fluid and its supplementation has been associated with improved oocyte 406 
quality and the retrieval of larger numbers of mature eggs after ovarian stimulation, 407 
suggesting that MTHFR plays an important role in oocyte maturation and development 53-55. 408 
Moreover, during maturation, human oocytes express receptors involved in folic acid 409 
transport, while in Xenopus oocytes efficient movement of folate across their membrane has 410 
been demonstrated 52, 56. 411 
With regards to the specific question of chromosomal abnormality, several publications have 412 
suggested the potential for a relationship between maternal MTHFR gene polymorphisms and 413 
aneuploid pregnancy or birth. Some authors have reported an association between MTHFR 414 
mutations and the risk of conceiving a child with Down syndrome 27, 28, 57, 58. The MTHFR 415 
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c.1298A>C polymorphism has been linked to chromosomal aneuploidy leading to Tuner 416 
Syndrome 59 and has also been proposed as an independent risk factor for spontaneous 417 
abortion with fetal chromosomal abnormality. Kim et al. 26 reported a higher prevalence of 418 
heterozygosity and homozygosity involving the MTHFR 1298C allele in women with 419 
spontaneous abortions associated with fetal aneuploidy compared to those with miscarriages 420 
of normal karyotype. However, some investigators have failed to confirm such a link 60, 61. 421 
Hassold an co-workers 29 observed a significant increase in the MTHFR c.677C>T polymorphism 422 
in mothers of trisomy 18 conceptuses but were unable to find associations with respect to 423 
other chromosomes.  424 
Data from the current study supports the notion that MTHFR mutations are associated with an 425 
increased risk of aneuploid pregnancy and that this is mostly attributable errors occurring 426 
during female meiosis. However, the underlying mechanism has not yet been elucidated. One 427 
hypothesis is that MTHFR mutations/polymorphisms lead to aberrant DNA methylation caused 428 
by abnormal folate metabolism and that this might increase the likelihood of meiotic 429 
aneuploidy 27, 29.  In the absence of sufficient folic acid, intracellular homocysteine 430 
accumulates, methinonine resynthesis is reduced and hence methylation reactions are 431 
compromised 62-64. Both clinical and experimental studies have shown that, in lymphocytes and 432 
liver cells, genomic DNA hypomethylation can be induced by deficiency of dietary folate, as 433 
well as other factors, and that this results in a variety of features such as abnormal gene 434 
expression, DNA strand breaks, chromosomal instability and aneuploidy 62, 65-67 . 435 
To our knowledge, the current study is the first to look at the influence of maternal and 436 
paternal MTHFR genotypes on the production of aneuploid preimplantation embryos. The 437 
evaluation of such an early developmental stage is particularly important when considering 438 
chromosomal abnormality because most aneuploid embryos are lost around the time of 439 
implantation. In previous studies, chromosome analyses were performed during the first 440 
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trimester of pregnancy, or even later. This is already far removed from the primary aneuploidy 441 
rate at conception.  442 
Origin of MTHFR polymorphisms 443 
The combined analysis of both c.677C>T and c.1298A>C polymorphisms in patients, controls 444 
and day-5 preimplantation embryos revealed linkage disequilibrium between the two loci. No 445 
individuals carrying three or four low-activity MTHFR alleles were found in any of the 446 
populations studied. These results are in agreement with several previous reports 18, 21, 22, 68, 69. 447 
The fact that certain combinations of alleles were not detected indicates that the two 448 
polymorphisms arose independently on two different wild type alleles. The close proximity of 449 
these polymorphisms to one another (2.1kb) is such that recombination between them is 450 
extremely unlikely to occur 21, 70, 71.  451 
Although concordant with most publications, our results contradict those of Isotalo et al. who 452 
found a considerable number of individuals homozygous for the MTHFR 677T allele and also 453 
heterozygous for the c.1298A>C polymorphism and proposed that the presence of 3 or 4 454 
mutant alleles might compromise fetal viability 72, 73. Results obtained in the present study do 455 
not support this hypothesis. Combinations of 3-4 mutant alleles were not observed in any of 456 
the 193 preimplantation embryos analysed, suggesting that such combinations of mutant 457 
alleles are either very rare or non-existent. The most likely explanation for the conflicting 458 
results found by Isotalo and colleagues is inaccuracy of the method for examining the 459 
c.1298A>C polymorphism 73, 74. The MboII RFLP method that they used has been criticised 460 
because of the potential for interference, and genotyping errors, caused by a silent 461 
polymorphism within the same exon of MTHFR. The problematic allele has a prevalence of 462 
approximately 5% in the Canadian population that they studied 21.  463 
 464 
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Embryo MTHFR genotype and chromosome abnormalities 465 
No significant differences in MTHFR c.677C>T and c.1298A>C genotype frequencies were seen 466 
when preimplantation embryos with and without chromosomal abnormalities were compared. 467 
This suggests that the increased frequency of aneuploidy observed in embryos derived from 468 
mothers carrying 677T and 1298C alleles occurs during meiosis, due to an affect in the oocyte 469 
or ovary rather than diminished MTHFR activity in the embryo itself. Complementary results 470 
were obtained by Bae et al. 69 who explored the prevalence of MTHFR c.677C>T and c.1298A>C 471 
genotypes later in development, after a pregnancy had been established. Their analysis of 472 
miscarriages indicated that the distribution of MTHFR c.677C>T and c.1298A>C genotypes was 473 
the same regardless of whether the products of conception were euploid or aneuploid. 474 
Embryo MTHFR genotype and implantation 475 
A significantly higher risk of implantation failure was observed in euploid embryos 476 
homozygous for MTHFR 677T. This indicates that the embryonic MTHFR c.677C>T genotype 477 
influences the ability of an embryo to form a successful pregnancy. Indeed, data from the 478 
current study suggest that homozygosity for 677T could play a role in approximately 20% of 479 
embryo implantation failures. Consequently, determination of the MTHFR genotype of IVF 480 
embryos, prior to choosing which embryo will be transferred to the uterus, is likely to prove 481 
highly advantageous for fertility treatments (e.g. IVF), maximising the probability that a viable 482 
embryo will be transferred.  483 
Defective folate metabolism has been shown to have negative effects on many essential 484 
processes that could impact embryogenesis and implantation, such as synthesis of nucleotide 485 
precursors for DNA synthesis and repair and cellular methylation reactions 5, 63, 64, 75. Early 486 
embryo development involves crucial cell division and differentiation, requiring coordinated 487 
spatial and temporal changes in gene expression 76. Disruption of DNA methylation, a 488 
fundamental feature of transcriptional modulation, is likely to have serious consequences for 489 
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the developing embryo 77. Other than affecting gene expression, the embryo MTHFR genotype 490 
could influence viability by introducing blood coagulation problems in the placenta, increasing 491 
the risk of miscarriage. Recent studies have shown that folic acid is potentially important in a 492 
number of crucial early stages of placental development, including extravillous trophoblast 493 
(EVT) invasion and angiogenesis 44. 494 
An important consideration, which warrants further research, is the possibility that the impact 495 
of MTHFR deficiency on embryo implantation could be mitigated by dietary folic acid 496 
supplementation (e.g. 500 µg daily as recommended for women that have had a fetus with a 497 
neural tube defect) 78. This may be particularly valuable for patients with a history of 498 
implantation failure following IVF treatment, especially if an adverse MTHFR genotype has 499 
been detected. Furthermore, the link between MTHFR deficiency and elevated aneuploidy risk, 500 
raises the intriguing question of whether increased folic acid intake in female carriers of 501 
MTHFR 677T and 1298C alleles could help to reduce the incidence of chromosomally abnormal 502 
embryos, thereby leading to improved outcomes of conception achieved naturally or using 503 
ART.  504 
Supplementation of embryo culture media, used during IVF treatments, should also be 505 
considered. We speculate that this might help to support homocysteine remethylation to 506 
methionine, assisting in the maintenance of the normal patterns of DNA methylation in 507 
embryos with reduced MTHFR activity. Currently, preimplantation embryos are routinely 508 
cultured in media that lack methyl donors. It would be valuable to determine whether folate-509 
supplemented media could reduce the risk of implantation failure, miscarriage or aneuploidy. 510 
Consideration should also be given to the impact of folate-supplementation on the incidence 511 
of imprinting disorders, associated with abnormal patterns of DNA methylation, which some 512 
studies suggest may be elevated in the conceptions of patients undergoing infertility 513 
treatments 79-81 514 
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In conclusion, a complex picture has emerged, in which MTHFR polymorphisms modulate 515 
reproductive success on several distinct levels. The data suggests that MTHFR genotype 516 
influences implantation, aneuploidy and the viability of euploid embryos. Multiple essential 517 
processes are affected, including meiosis, embryogenesis and initiation of pregnancy. Based 518 
upon the findings of this study, MTHFR joins a rare group of human genes displaying an 519 
example of heterozygote disadvantage and another select group of genes with the ability to 520 
influence aneuploidy rates. Given the relative ease with which embryonic MTHFR genotype 521 
can be determined, the two polymorphisms may represent valuable new biomarkers for the 522 
assessment of embryo competence, potentially enhancing IVF treatments by helping to reveal 523 
the embryos most likely to produce a viable pregnancy. Another exciting possibility is that 524 
cellular pathways dependent on MTHFR could be supported through maternal dietary 525 
supplementation or, for embryos produced using ART, via the addition of folate to culture 526 
medium. While this remains highly speculative, the potential benefits, in terms of reduced 527 
risks of implantation failure, aneuploidy, abnormal imprinting and miscarriage, argue that 528 
work to examine these possibilities should be encouraged as a matter of urgency. 529 
 530 
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 783 
FIGURE TITLES AND LEGENDS 784 
Figure 1. Distribution of MTHFR c.677C>T and c.1298A>C genotypes in the study groups. (A) 785 
MTHFR c.677C>T genotype frequencies in subfertile and fertile control groups. (B) MTHFR 786 
c.1298A>C genotype frequencies in subfertile and fertile control groups. X2 test was used to 787 
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estimate whether the genotypic frequencies differed significantly among the study groups. 788 
Significantly different groups (p<0.05) are highlighted with an asterisk.     789 
 790 
Figure 2. Distribution of MTHFR c.677C>T genotypes in chromosomally normal embryos with 791 
successful and failed implantation. X2 test was used to estimate whether the genotypic 792 
frequencies differed significantly among the study groups. Significantly different groups 793 
(p<0.05) are highlighted with an asterisk. 794 
 795 
Figure 3. Implantation failure incidence associated to embryonic MTHFR c.677C>T genotype. 796 
The frequency of implantation failure in embryos presenting different MTHFR c.677C>T 797 
genotypes is presented. 798 
TABLES 799 
Table 1. MTHFR allele frequencies for fertile control and subfertile groups. X2 test was used 800 
to estimate whether the allelic frequencies differed significantly among the study groups. 801 
 
MTHFR allele 
Allele frequency 
Fertile control group  Subfertile group 
677C 0.696 0.725 
677T 0.304 0.275 
1298A 0.727 0.647* 
1298C 0.273 0.353* 
               * Groups are significantly different to control, X2 test, p<0.05  802 
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Table 2. Individual MTHFR c.677C>T and c.1298A>T genotype frequencies for fertile control 803 
and subfertile groups according to the sex of the patient. X2 test was used to estimate 804 
whether the genotypic frequencies differed significantly among the study groups. 805 
 
 
genotype 
Frequency 
Fertile control 
group  
Female subfertile 
group  
Male subfertile 
group  
677CC 0.516 0.620 0.500 
677CT 0.360 0.272 0.326 
677TT 0.124 0.109 0.174 
1298AA 0.509 0.396* 0.444 
1298AC 0.435 0.473 0.467 
1298CC 0.056 0.132* 0.089 
* Groups are significantly different to control, X2 test, p<0.05 806 
Table 3. Individual MTHFR c.677C>T and c.1298A>C genotype frequencies for fertile control 807 
group and different indication groups of subfertile patients. X2 test was used to estimate 808 
whether the genotypic frequencies differed significantly among the study groups. RIF: 809 
Repetitive implantation failure; RM: Recurrent miscarriage; AMA: advanced maternal age. 810 
 
MTHFR 
genotype 
Frequency 
Fertile control 
group  
RIF group 
 
RM group 
 
AMA group 
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677CC 0.516 0.525 0.588 0.588 
677CT 0.360 0.275 0.275 0.353 
677TT 0.124 0.200 0.137 0.059 
1298AA 0.509 0.447 0.471 0.353 
1298AC 0.435 0.316 0.451 0.588 
1298CC 0.056 0.237* 0.078 0.059 
* Groups are significantly different to control, X2 test, p<0.05 811 
Table 4. Mean embryo aneuploidy rates (mean ± SEM) of patients with different MTHFR 812 
677/1298 genotypes. T-test was used to assess whether the abnormality rates differed 813 
significantly among genotypes within the study groups. 814 
 Mean Embryo Aneuploidy Rate (%) 
 677CC/1298AA Other genotypes  
(≥ 1 minor allele) 
P-value 
Subfertile group 58.76±6.3 70.22±2.19 0.036* 
Female subfertile group 54.58±10.04 71.03±2.67 0.028* 
Male subfertile group 64.74±5.57 69.21±3.65 0.514 
AMA group 58.14 ± 9.41 75.00 ± 2.96 0.045* 
RM group 51.65 ± 12.83 74.40 ± 4.52 0.048* 
RIF group 62.67 ± 8.40 65.48 ± 3.51 0.721 
* Groups are significantly different, T-test, p<0.05 815 
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